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Abstract
Introduction: Exsanguination due to uncontrolled bleeding is the leading cause of potentially preventable deaths
among trauma patients. About one third of trauma patients present with coagulopathy on admission, which is
associated with increased mortality and will aggravate bleeding in a traumatized patient. Thrombelastographic
(TEG) clot strength has previously been shown to predict outcome in critically ill patients. The aim of the present
study was to investigate this relation in the trauma setting.
Methods: A retrospective study of trauma patients with an injury severity qualifying them for inclusion in the
European Trauma Audit and Research Network (TARN) and a TEG analysis performed upon arrival at the trauma
centre.
Results: Eighty-nine patients were included. The mean Injury Severity Score (ISS) was 21 with a 30-day mortality of
17%. Patients with a reduced clot strength (maximal amplitude < 50 mm) evaluated by TEG, presented with a
higher ISS 27 (95% CI, 20-34) vs. 19 (95% CI, 17-22), p = 0.006 than the rest of the cohort. Clot strength correlated
with the amount of packed red blood cells (p = 0.01), fresh frozen plasma (p = 0.04) and platelet concentrates (p =
0.03) transfused during the first 24 hours of admission. Patients with low clot strength demonstrated increased 30-
day mortality (47% vs. 10%, p < 0.001). By logistic regression analysis reduced clot strength was an independent
predictor of increased mortality after adjusting for age and ISS.
Conclusion: Low clot strength upon admission is independently associated with increased 30-day mortality in
trauma patients and it could be speculated that targeted interventions based on the result of the TEG analysis may
improve patient outcome. Prospective randomized trials investigating this potential are highly warranted.
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Introduction
Exsanguination due to uncontrolled bleeding is the lead-
ing cause of potentially preventable deaths among
trauma patients [1-3]. Upon arrival at the hospital,
about one third of all trauma patients present with coa-
gulopathy [4-6], which is associated with increased
transfusion requirements, development of multi organ
failure and death [5-7]. The presence of coagulopathy
will aggravate active hemorrhaging in traumatized
patients.
Coagulopathy associated with traumatic injury has his-
torically been described as the result of multiple envir-
onmental factors such as acidemia and hypothermia,
which have been shown to independently impair blood
clotting [4,7,8]. Combined with dilution and consump-
tion of coagulation factors and platelets secondary to
fluid administration and bleeding, severe coagulopathy
ensues [5,7]. Recently, an early acute traumatic coagulo-
pathy induced by the trauma and hypoperfusion, leading
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activation of systemic anticoagulant and fibrinolytic
pathways, has been described [7].
Early monitoring of coagulation is essential to identify
coagulopathy and this is routinely based on conventional
plasma based coagulation tests such as prothrombin
time (PT), activated partial thromboplastin time
(APTT), international normalized ratio (INR), fibrinogen
and platelet number [3]. These plasma-based tests only
reflect the initiation of the hemostatic process [9] and
they cannot be used for evaluating the amplification of
propagation parts or increased fibrinolysis [7]. Thrombe-
lastography (TEG)/thrombelastometry (ROTEM) ana-
lyses the viscoelastic properties of whole blood, thereby
reflecting the entire hemostatic process. TEG therefore
allows evaluation of coagu l a t i o ni nw h o l eb l o o da n d
comprises a more qualitative analysis of the individual
cellular components and their interactions [10-12]. Vis-
coelastic hemostatic assays such as TEG are currently
recommended by several international guidelines and
teaching books concerning massive transfusion in
trauma [3,13,14]. Furthermore, TEG is the only test
available for rapid identification of hyperfibrinolysis,
which is associated with increased mortality in trauma
patients [15-17]. A schematic TEG trace is shown in
Figure 1. In TEG, the hemostatic process is described by
several measurements: R (reaction) time is the period
from the beginning of the test until clot formation
begins. a-angle reflects the increase in clot strength
over time, and the maximal amplitude (MA) is a direct
measure of the highest point on the TEG curve, repre-
senting maximal clot strength. Ly30 is a measurement
of the fibrinolytic activity during the first 30 minutes
after MA. MA is influenced primarily by platelet con-
centration and function [10,11]. Low MA has been
reported to be the best TEG indicator of increased
transfusion requirements and mortality [18,19]. Transfu-
sion therapy guided by TEG has been shown to reduce
peri- and postoperative bleeding and transfusion
requirements, thereby improving survival rates for mas-
sively bleeding patients [20].
In trauma, TEG has been described as a better predic-
tor of transfusion requirements than PT, INR or APTT
[18] and recently, initial experiences with TEG-guided
management of life-threatening post-injury coagulopathy
was reported by Kashuk and colleagues with a favour-
able outcome when comparing with historic controls
[21]. These results align with Schöchl et al. who found a
beneficial effect of goal-directed resuscitation in actively
bleeding trauma patients when juxtaposed to the patient
outcome predicted by trauma and injury severity score
(TRISS) [22]. With the consistent findings that low clot
strength is associated with poor outcome in trauma
patients [15,18], this end-point together with transfusion
requirements have been chosen in the present study
concerning patients suffering major trauma.
Methods
A retrospective study including trauma patients from
2006 and 2007, who were admitted at the Trauma Cen-
tre at Rigshospitalet, Copenhagen. The inclusion criteria
were: The patients should be included in the European
Trauma Audit and Research Network (TARN) [23,24],
and have a TEG analysis performed along with the
initial blood tests sampled upon arrival at the hospital,
which occurs before any blood products are adminis-
tered. TARN is a joint European database containing
uniform reports on all included trauma patients. Only
including patients with severe traumatic injuries, this
database provides access to comparable patient data in
the specified time period. Data was collected using sev-
eral databases. Gender and age were registered using the
Danish civil registration numbers. A review of patient
charts and TARN-records revealed mechanism and type
of traumatic injury and Injury Severity Score (ISS)
[23,25]. TEG was performed in the blood bank on
citrated blood samples within 5-7 min of blood sampling
in accordance with our previously published experience
Figure 1 Thrombelastographic analysis with measured parameters. Reaction time (R). Alpha angle (a), maximal amplitude (MA), lysis (LY).
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trauma center allowing for immediate interpretation and
intervention as described elsewhere [27]. TEG (TEG
5000, Haemoscope, Niles, IL) parameters of R-time, a-
angle and maximal amplitude (MA) and laboratory para-
meters such as hemoglobin and platelet count (Sysmex
2100, Sysmex Corp., Kobe, Japan), APTT and INR (ACL
TOP, Beckman Coulter Inc., Brea, CA), lactate and
blood glucose (Modular P-modul, Hitachi, Tokyo,
Japan) including the number and time for delivery of
packed red blood cells (RBC), fresh frozen plasma (FFP)
and platelet concentrates (PC) were collected using the
Regional Blood Bank Database. Data on hospital length
of stay and 30-day mortality was collected using the
hospital registration system.
Patients were categorized as having reduced clot
strength if MA was lower than the cut-off value sup-
plied from the manufacturer at time of analysis, MA <
50 mm.
Statistics
Distributions of data were inspected using probability
plots, and non-normal distributed variables were log-
transformed. Data on patients stratified according to
MA < 50 mm were compared by student-T test. Asso-
ciations of mortality and MA < 50 mm, APTT, blood
glucose, hemoglobin, blood lactate, INR or platelet
counts were analyzed by multivariable regression includ-
ing co-variables of age and ISS, using 30-day mortality
(yes/no) as dependent variable. Values are presented as
means with 95% Confidence Intervals and results of
multivariable regression analyses are presented as Odds
Ratio (OR) with X
2.A r e au n d e rt h ec u r v e( A U C )u s i n g
Receiver Operating Characteristic (ROC) was calculated
t oc o m p a r er e l a t i v ep r o g n o s t i ce f f i c i e n c yf o r3 0 - d a y
mortality on each assay. P-values < 0.05 were considered
significant. Statistical calculations were performed using
SPSS 17 (IBM Corp., Somers, NY).
Results
Demographics of the 89 included patients are presented
in Table 1. The vast majority presented with blunt inju-
ries, and 65 out of the 89 patients suffered injuries relat-
ing to traffic accidents. The mean ISS of the cohort was
21 and the 30-day mortality was 17%.
Patients with reduced clot strength presented with
higher ISS 27 (95% CI, 20-34) vs. 19 (95% CI, 17-22), p
= 0.006 than the rest of the cohort.
With regards to standard laboratory parameters,
hemoglobin and platelet counts were lower in patients
with low clot strength compared to the rest of the
cohort [9.7 (95% CI 8.5-10.7) vs. 11.9 (95% CI, 11.5-
12.4) g/dL, p < 0.001 and 140 (95% CI, 112-168) vs.
214 (95% CI, 196-231) × 10
9/L, p < 0.001,
respectively]. APTT and INR were higher in patients
with reduced clot strength when compared to the rest
of the cohort [49 (95% CI, 37-66) vs. 29 (95% CI, 27-
30) seconds, p < 0.001 and 1.4 (95% CI, 1.3-1.5) vs. 1.2
(95% CI, 1.1-1.2) arbitrary units, p < 0.001, respec-
tively]. Glucose was also higher in patients with low
clot strength [10.3 (95% CI, 8.7-12.1) vs. 7.7 (95% CI,
7.2-8.3) mmol/L, p = 0.001].
During the first 24 hours of admission, patients with
reduced clot strength received approximately twice as
many blood products compared with the rest of the
cohort (Table 2), and there was a significant correlation
between clot strength and the amount of transfused
RBC (p = 0.01), FFP (p = 0.04), and PC (p = 0.03).
Patients presenting with low clot strength demonstrated
increased 30-day mortality (47% vs. 10%, p < 0.001). In
patients with low clot strength, 7 out of 8 patients
expired within the first 48 hours from hospital admis-
sion (Figure 2).
By logistic regression analysis with 30-day mortality as
endpoint, reduced clot strength was an independent pre-
dictor of increased mortality after adjusting for age and
ISS (Table 3).
Table 1 Patient demographics (n = 89)
Age (years) 39 (35-43)
Males 59 (66%)
Blunt trauma 76 (85%)
Cause of trauma
Traffic accident 65
Fall from heights 10
Assault 10
Suicide attempt 4
Type of trauma
Thoracic 15
Abdominal 7
Extremities 4
Cerebral 18
Multi trauma 37
Other 8
Injury Severity Score 21 (19-23)
Transfusions in units
RBC 3.4 (2.6-4.4)
FFP 2.2 (1.7-2.8)
PC 1.6 (1.4-1.9)
Length of stay (days) 10.3 (8.1-13.1)
Thirty-day mortality 15 (17%)
Demographics of the 89 patients included in the study. Frequencies are stated
as count with percentage in parenthesis. Age, Injury Severity Score, blood
product transfusions and length of stay are stated as means with 95%
Confidence Intervals. Packed red blood cells (RBC), fresh frozen plasma (FFP)
and platelet concentrates (PC).
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square = 18.8, p = 0.008), glucose (OR = 1.4 (95% CI,
1.1-1.8), chi-square = 15.6, p = 0.002) and lactate (OR =
1.4 (95% CI, 1.1-1.9), chi-square = 8.5, p = 0.007) were
also associated with 30-day mortality after adjusting for
age and ISS.
Relative prognostic efficiency for 30-day mortality
using ROC AUC was for APTT 0.78 (95% CI, 0.61-0.95)
p < 0.001, for INR 0.63 (95% CI, 0.44-0.81) p = 0.13 and
for MA 0.70 (95% CI, 0.53-0.86) p = 0.02 (Figure 3).
Only one patient presented with pathologically
increased fibrinolysis, 54% (normal < 8%). This patient
also demonstrated reduced clot strength, had the highest
ISS in the cohort (66) and expired on the day of
admission.
Discussion
The main finding of the present study was that low clot
strength evaluated by TEG was independently associated
with increased mortality at 30-days post trauma, also
after adjusting for ISS and age. To our knowledge, this
is the first study reporting of an independent association
between reduced clot strength upon admission and 30-
day mortality in trauma patients. Recently, Kashuk et al.
found a similar association between low clot strength
and 24-hour survival in trauma patients [21]. Our
results correspond to the findings of Carroll et al., who
in 161 trauma patients found that non-survivors pre-
sented with significantly lower clot strength compared
to survivors [15]. Abnormally reduced clot strength has
also previously been reported to be associated with
Table 2 Patients stratified according to clot strength
Low clot strength
n=1 7
Normal or high clot strength
n=7 2
p-value
Age (years) 43 (32-54) 38 (34-43) 0.38
Males 10 (59%) 49 (68%) 0.47
Blunt trauma 16 (94%) 60 (83%) 0.45
Type of trauma 0.66
Thoracic 1 14
Abdominal 1 6
Extremities 0 4
Cerebral 5 13
Multi trauma 8 29
Other 2 6
Injury Severity Score 27 (20-34) 19 (17-22) 0.006
Laboratory analyses
Hemoglobin (g/dL) 9.7 (8.5-10.7) 11.9 (11.5-12.4) <0.001
Platelet count (10
9/L) 140 (112-168) 214 (196-231) <0.001
APTT (seconds) 49 (37-66) 29 (27-30) <0.001
INR (arbitrary units) 1.4 (1.3-1.5) 1.2 (1.1-1.2) <0.001
Glucose (mmol/L) 10.3 (8.7-12.1) 7.7 (7.2-8.3) 0.001
Lactate (mmol/L) 3.3 (2.4-4.6) 2.5 (2.1-2.9) 0.11
TEG
R (minutes) 6.3 (5.2-7.4) 5.2 (4.9-5.5) 0.01
Angle (degrees) 47 (40-53) 65 (63-67) 0.001
MA (mm) 39 (34-44) 60 (59-61) N/A
Ly30 (%) 0.8 (0.0-1.7) 0.7 (0.5-0.9) 0.58
Transfusions in units
RBC 6.4 (3.7-11.2) 2.9 (2.2-3.8) 0.02
FFP 3.6 (1.9-6.6) 2.0 (1.5-2.6) 0.06
PC 2.3 (1.5-3.6) 1.5 (1.2-1.7) 0.04
Length of stay (days) 4.9 (2.7-8.7) 12.3 (9.6-15.7) 0.002
Data of patients with low clot strength (maximal amplitude < 50 mm) compared to patients with normal or high clot strength (maximal amplitude ≥ 50 mm).
Frequencies are stated as count with percentage in parenthesis. Age, laboratory and thrombelastographic (TEG) analyses, blood product transfusions, Injury
Severity Score and length of stay are stated as means with 95% Confidence Intervals. Activated partial thromboplastin time (APTT), international normalized ratio
(INR), packed red blood cells (RBC), fresh frozen plasma (FFP), platelet concentrates (PC).
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intensive care unit, reflecting the clinical significance of
whole blood viscoelastic hemostatic assays such as TEG
in critically ill patients [19]. The association between
reduced clot strength upon hospital admission, increased
transfusion requirements and high 30-day mortality may
reflect that patients with reduced clot strength more fre-
quently develop life-threatening bleedings and thereby
experience more episodes of hypoperfusion. This is indi-
cated by the increased lactate in these patients when
compared to those with normal clot strength. Conse-
quently, normalizing hemostasis in these patients may
improve outcome. In alignment with this, we have pre-
viously demonstrated that early aggressive administra-
tion of plasma and platelets in addition to RBC can
reverse the acute coagulopathy of trauma found by TEG
[26]. This transfusion strategy reduces mortality in
massively bleeding patients [20], indicating that goal-
directed therapy based on TEG may improve outcome.
This corresponds to the findings of Kashuk et al., who
reported that using TEG for management of life-threa-
tening postinjury coagulopathy was associated with a
favourable outcome when compared to historic controls
[21].
An independent association between APTT and 30-
day mortality aligns well with the findings of Brohi et al.
and Macleod et al. who reported that a substantial pro-
portion of trauma patients upon admission presented
with coagulopathy unrelated to resuscitation fluids and
hypothermia, and that this was associated with a 3-4
fold increased mortality [4,6]. Interestingly, plasma
based coagulation assays have consistently been shown
not to correlate to relevant clinical bleeding conditions
[28] and consequently, in trauma patients, mild
Figure 2 Mortality in patients with low vs. non-low clot strength.
Table 3 Prediction of mortality by low clot strength, age and Injury Severity Score
OR 95% CI p-value X
2
Injury Severity Score (per point) 1.09 (1.01-1.16) 0.02 6.6
Age (per year) 1.03 (1.00-1.06) 0.09 3.0
Low clot strength (maximal clot strength < 50 mm) 5.00 (1.22-20.45) 0.03 4.8
Multivariable analysis of age, Injury Severity Score and low clot strength (maximal amplitude < 50 mm) with 30-day mortality as dependent variable.
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thing else of relevance for outcome in these severely
injured patients. In the present study, APTT demon-
strated the best ROC characteristics with regard to mor-
tality, and we speculate that this reflects the degree of
endothelial breakdown [29]. Supporting this, we recently
found that severely injured trauma patients presented
with increased glycocalyx and endothelial breakdown,
evaluated by syndecan-1 and soluble thrombomodulin
(sTM) in plasma, respectively. Constituents of the glyco-
calyx such as heparansulphate and syndecan-1 together
with endothelial sTM all have potent anticoagulant
properties, and this may be reflected by increased APTT
[30].
Brohi and coworkers coined the term ACoTS to
d e s c r i b et h i sa c u t ec o a g u l o p a t h yo ft r a u m a[ 3 1 ] .I th a s
been postulated that the most important factors leading
to this condition are tissue injury and shock, and that
the coagulopathy identified by increased APTT and PT
is a result of activation of the protein C system together
with increased fibrinolysis [32]. The importance of tissue
hypoperfusion for outcome of trauma patients, as sug-
gested by Brohi et al. [7], corresponds well with our
finding of lactate being independently associated with
30-day mortality also after adjusting for ISS and age.
The relevance of blood lactate for mortality in trauma
patients was recently reported by Vandromme et al.
[33]. When comparing patients with reduced clot
strength to the rest of the cohort, the hypocoagulable
patients were more seriously injured as reflected by a
higher ISS. Carroll et al. and Kaufmann et al. also
reported that trauma patients with evidence of TEG
hypocoagulability had higher ISS than those presenting
with normal or hypercoagulable TEG profiles [15,34].
The hypocoagulable TEG may reflect increased con-
sumption of coagulation factors and platelets secondary
to the trauma, thus displaying disseminated intravascu-
lar coagulation (DIC) with a hemorrhagic phenotype
[35] or, as discussed previously, ACoTS [7], or perhaps
a combination. The standard coagulation analyses such
as APTT and INR were prolonged in TEG hypocoagul-
able patients, and this may be ascribed to both DIC
with a hemorrhagic phenotype and ACoTS, whereas the
reduced platelet count in hypocoagulable patients might
indicate a consumptive state.
Hyperfibrinolysis has been reported to be an integral
p a r to ft h ec o a g u l o p a t h yo ft r a u m a[ 3 6 ]a n dS c h ö c h le t
al. has reported that this condition is observed in the
most seriously injured patients, and is associated with
elevated mortality [16]. This corresponds to the findings
Figure 3 ROC curves for APTT, INR and MA in relation to mortality. Activated partial thromboplastin time (APTT), international normalized
ratio (INR), maximal amplitude (MA).
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highest ISS of the entire cohort presented with increased
fibrinolysis.
In the present study, patients with hypocoagulable
TEG received twice as many blood product transfusions
during the first 24 hours of admission than the rest of
the cohort. A significant correlation between clot
strength and the amount of transfused RBC, FFP and
PC was found. Plotkin et al. reported that in combat
trauma patients, thrombelastography was a more accu-
rate indicator of blood product requirements than PT,
APTT and INR [18]. Furthermore, Kaufmann et al.
found that only ISS and TEG were predictive of transfu-
sions, whereas PT and APTT were not [34]. The super-
iority of TEG in identifying clinically relevant
coagulopathies and blood product requirements can be
explained by the introduction of the cell-based model of
hemostasis. This emphasizes the role of platelets for
intact thrombin generation and highlights the impor-
tance of the dynamics in thrombin generation, which
affect the quality and stability of the thrombus formed
[37]. Consequently, hemostatic assays performed on
plasma such as APTT and PT are of limited value [38]
and do not correlate with clinically relevant coagulopa-
thies or bleeding conditions [28]. To date, more than 25
studies including more than 4,500 patients have evalu-
ated TEG versus conventional coagulation assays on
bleeding and transfusion requirements in surgical
patients undergoing cardiac, liver, vascular or trauma
surgery and in patients requiring massive transfusion.
These studies all report that whole blood TEG is super-
ior in predicting the need for blood transfusion, and
that treatment based on the results of the TEG analysis
reduces transfusion requirements and the need for re-do
surgery in contrast to treatments relying on plasma
based coagulation assays [11]. Early identification and
institution of goal-directed treatment of post-traumatic
coagulopathy could, potentially, improve outcome in
trauma patients as indicated in the studies performed by
Kashuk et al. and Schöchl et al. [21,22].
Our results are subject to limitations inherent to
observational studies and thereby do not allow indepen-
dent estimation of the cause-and-effect relationship
between the TEG results and outcome. The results of
this study indicate an association rather than a correla-
tion between low clot strength and mortality post-
trauma. Furthermore, this is a retrospective study, which
was conducted in a limited number of patients at a sin-
g l ec e n t r ea n d ,a l t h o u g hi n t e r nal validity is high, exter-
nal validity may be limited. Another limitation of the
present study is, that the reported changes of TEG para-
meters had to be interpreted on the basis of external
reference values. The clinical inhibitory effect of antith-
rombotic medications such as clopidogrel and aspirin on
platelet aggregation cannot be assessed using hemostatic
assays, because the assay activators cancel this inhibi-
tion. Nor will conditions affecting the endothelium such
as von Willebrand disease be detected by hemostatic
assays [11].
Conclusions
Low clot strength in trauma patients, evaluated by TEG
upon admission to the trauma centre is independently
associated with increased 30-day mortality, even after
adjusting for age and ISS. We believe that targeted
interventions with plasma and platelets in addition to
RBC together with antifibrinolytic therapy, based on the
results of the TEG analysis, may improve outcome in
trauma patients. Prospective randomized trials investi-
gating this potential are highly warranted.
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